×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Companies To Watch OSE Immunotherapeutics
Life Science Leader
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in...
1 month ago
OSE shares pipeline updates and plans Phase III trial for Tedopi
Pharmaceutical Technology
The French company will start the confirmatory trial for its cancer vaccine Tedopi as a second-line lung cancer therapy in Q2 2024.
3 months ago
AbbVie Puts Potential $713M on the Line for OSE’s Inflammation Antibody
BioSpace
AbbVie continued its dealmaking spree Wednesday by partnering with OSE Immunotherapeutics to develop its early-stage, first-in-class...
2 months ago
AbbVie pays $48M for OSE's preclinical chronic inflammation drug
Fierce Biotech
AbbVie is talkin' bout a resolution. The Big Pharma has bet $48 million on OSE Immunotherapeutics' antibody platform, handing the biotech...
2 months ago
AbbVie, OSE Partner On MAbs For Chronic Inflammation
Contract Pharma
OSE to receive an $48 million upfront and is eligible to receive up to an additional $665 million in milestones.
2 months ago
AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation
PharmTech
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating...
2 months ago
AbbVie inks $713m deal for OSE chronic inflammation drug
Pharmaphorum
AbbVie adds to its immunology and inflammation pipeline, paying $48m upfront for rights to a preclinical ChemR23 antibody developed by OSE...
2 months ago
OSE Immunotherapeutics' Global License to Develop a Novel
GlobeNewswire
OSE Immunotherapeutics' Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective...
1 month ago
OSE Immunotherapeutics shares soar on AbbVie deal news
The Pharma Letter
French immunotherapy company OSE Immunotherapeutics was trading more than 50% higher by late Wednesday.
2 months ago
OSE Immunotherapeutics Announces H1 2023 Results and Provides Corporate Update
Business Wire
Financial visibility secured over the next 12 months, until Q4 2024, supported by additive financing secured in H1-2023 and reduction of...
7 months ago